➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKesson
AstraZeneca
Colorcon
Harvard Business School

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

PEPCID RPD Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Pepcid Rpd, and when can generic versions of Pepcid Rpd launch?

Pepcid Rpd is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PEPCID RPD is famotidine. There are eighteen drug master file entries for this compound. Ninety-two suppliers are listed for this compound. Additional details are available on the famotidine profile page.

US ANDA Litigation and Generic Entry Outlook for Pepcid Rpd

A generic version of PEPCID RPD was approved as famotidine by ATHENEX INC on April 16th, 2001.

  Start Trial

Summary for PEPCID RPD
Drug patent expirations by year for PEPCID RPD
Recent Clinical Trials for PEPCID RPD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Novotech (Australia) Pty LimitedPhase 1
Calithera Biosciences, IncPhase 1
University of Maryland, BaltimorePhase 2

See all PEPCID RPD clinical trials

US Patents and Regulatory Information for PEPCID RPD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-001 May 28, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-002 May 28, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PEPCID RPD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-002 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-001 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-002 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-001 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-001 May 28, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKinsey
McKesson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.